Pfizer clinical director calls for better understanding of e-patients

Share this article:
A senior Pfizer R&D executive is calling for clinical trials to make better use of the phenomenon of the “empowered e-patient” – but admits that highly interactive e-patients can pose challenges to the data collection process.

“While there is not always much room to innovate [within trials], there are ways to partner with e-patients to improve awareness, assist with recruitment and retention, report outcomes, and share data and learnings,” Craig Lipset, senior director, clinical research at Pfizer, told a packed room of delegates at the e-Patient Connections conference in Philadelphia this morning.

Lipset believes there are a couple of things that can be done immediately. “First, we need to make clinical trials more patient-centric and less investigator-centric,” he said, explaining that the conventional wisdom of centering investigations around trial centers effectively creates “hub-and-spoke models” that can restrict the scope and scale of studies. (“Could patients participate from home or use their mobile phones?” he asks.)

Second, Lipset suggests that trials could become more participatory by sharing data and learnings with subjects, which could, in turn, improve patients' experiences and outcomes. He cited the example of making bloodwork data from the trials available to the participants' own physicians, which, at the very least, might save patients the expense of paying for it again. Lipset also believes in sharing the study results with patients.
“Anyone who shares their body in a trial,” he said, “should get the learnings back.”

Lipset warned, however, of the potentially adverse effects of working with a group of highly interactive, empowered patients in a blinded, randomized study because they might share observations about adverse events or discuss which group they might be in. “We can't stop those conversations,” he said, “but we need to understand them as they affect how we interpret the data.”

According to Lipset, Pfizer is having internal discussions about a number of possible initiatives for integrating, utilizing and exchanging value with empowered patients during clinical research.
Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Thursday, August 21

Five things for pharma marketers to know: Thursday, ...

An Ebola survivor is set to leave Emory University Hospital, but the cause of the cure is uncertain, the FDA has approved a new type 1 diabetes test, and the ...

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Gaucher disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.